Health Library Explorer
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z A-Z Listings Contact Us
Related Reading
Translate

Zydelig Approved for Three Types of Blood Cancer

WEDNESDAY, July 23, 2014 (HealthDay News) -- Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release.

The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said.

The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash.

Zydelig is marketed by Gilead Sciences, based in Foster City, Calif.

More information

The FDA has more about this approval.

Online Medical Reviewer: Louise Akin, RN, BSN
Online Medical Reviewer: Daphne Pierce-Smith, RN, MSN, FNP, CCRC
Date Last Reviewed: 7/23/2014
Copyright ©2013 HealthDay. All rights reserved.
Powered By Krames StayWell
Copyright © Krames StayWell except where otherwise noted.
About Us
  • Follow Us On:
  • Facebook
  • Twitter
  • Health Hub
  • Pinterest
  • Google+
  • YouTube
  • RSS
  •  
  • Bookmark and Share
© Brigham and Women's Hospital | 75 Francis Street, Boston MA 02115 | 617-732-5500